Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.

Tempus AI, Inc. Class A Common Stock

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. 

Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. 

For more information, visit tempus.com and follow us on Twitter (@TempusLabs). 

Tempus AI

Our founder and CEO, Eric Lefkofky, joins mHUB for next week's HardTech Summit to discuss his path to #AI enabled healthcare. Register here: https://tempus.co/4c2W6Q2 

Dr. Ezra Cohen’s personal passion for taking care of cancer patients led him from decades of clinical care and research to Tempus as our Chief Medical Officer of Oncology. In our #TempusWhy series, Dr. Cohen shares how our work at Tempus fuels his unwavering commitment and determination to advancing cancer care. 

Hear more: 

Physicians like Dr. James and their care teams seamlessly use Tempus One to make informed patient treatment decisions through convenient functionalities that deliver insights on patient’s full clinical and molecular profile. By improving clinical workflows, One can allow more time for teams to focus on patient care. Learn more about Tempus One: https://tempus.co/42ZDYT4 

We’re looking forward to being on-site this week at the Liquid Biopsy for Precision Oncology Summit. Attend Adam Morabito’s presentation on how emerging technologies and multi-modal data have unlocked novel use cases for tumor-naïve liquid biopsies. Learn more: https://tempus.co/4bIlHha 

We’re #NowHiring for a Territory Sales Executive to join our team in North Atlanta. This position will drive new opportunities with major US cancer centers, clinics, and oncology practices. Join our growing sales team by applying here: https://bit.ly/3T6HkjX #atljobs 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	62.06M -	188.00M 202.95%	257.85M 37.15%	320.67M 24.36%	531.82M 65.85%
cost of revenue	46.02M -	165.18M 258.96%	180.46M 9.26%	198.99M 10.26%	245.65M 23.45%
gross profit	16.04M -	22.83M 42.31%	77.39M 238.99%	121.68M 57.23%	286.18M 135.18%
selling and marketing expenses
general and administrative expenses
selling general and administrative expenses	78.96M -	125.48M 58.92%	193.02M 53.82%	229.94M 19.13%	296.76M 29.06%
research and development expenses	56.86M -	91.28M 60.52%	128.35M 40.62%	160.88M 25.34%	185.50M 15.30%
other expenses		-466K -	-316K 32.19%	-4.85M 1,433.54%	21.82M 550.31%
cost and expenses	181.84M -	381.94M 110.04%	501.83M 31.39%	589.81M 17.53%	727.90M 23.41%
operating expenses	135.82M -	216.76M 59.59%	321.37M 48.26%	390.82M 21.61%	482.26M 23.39%
interest expense		18.93M -	15.18M 19.78%	21.89M 44.19%	46.87M 114.07%
ebitda	-104.76M -	-170.88M 63.11%	-220.10M 28.80%	-238.73M 8.47%	-133.33M 44.15%
operating income	-119.78M -	-193.93M 61.91%	-243.98M 25.81%	-269.14M 10.31%	-196.08M 27.15%
depreciation and amortization	15.02M -	23.05M 53.48%	23.88M 3.60%	30.41M 27.34%	33.33M 9.61%
total other income expenses net	4.83M -	-17.42M 460.70%	-14.61M 16.15%	-20.01M 36.95%	21.82M 209.07%
income before tax	-114.95M -	-211.35M 83.86%	-258.59M 22.35%	-289.15M 11.82%	-213.53M 26.15%
income tax expense	33.19M -	-1.50M 104.52%	604K 140.27%	66K 89.07%	288K 336.36%
net income	-148.14M -	-209.85M 41.66%	-259.19M 23.51%	-289.81M 11.81%	-214.12M 26.12%
weighted average shs out	61.35M -	169.88M 176.91%	169.88M 0%	169.88M 0%	159.88M 5.88%
weighted average shs out dil	61.35M -	169.88M 176.91%	169.88M 0%	169.88M 0%	159.88M 5.88%
eps	-2.41 -	-1.24 48.55%	-1.53 23.39%	-1.71 11.76%	-1.34 21.64%
epsdiluted	-2.41 -	-1.24 48.55%	-1.53 23.39%	-1.71 11.76%	-1.34 21.64%

TEM

COM:TEMPUS

Tempus

Last Close

56.79

08/11 21:00

Market Cap

5.77B

Beta: -

Volume Today

2.92M

Avg: -

Preview